Second-Line Switch to Dolutegravir for Treatment of HIV Infection
Ombajo, Loice A., Penner, Jeremy, Nkuranga, Joseph, Mecha, Jared, Mburu, Margaret, Odhiambo, Collins, Ndinya, Florentius, Aksam, Rukia, Njenga, Richard, Wahome, Simon, Muiruri, Peter, Eshiwani, Sheila, Kimani, Maureen, Ngugi, Catherine, Pozniak, Anton
Published in The New England journal of medicine (22.06.2023)
Published in The New England journal of medicine (22.06.2023)
Get full text
Journal Article
Switching treatment-experienced, integrase inhibitor-naïve, virally suppressed HIV-1 infected adults from ritonavir-boosted protease inhibitors to dolutegravir: design, methods, and baseline results of a randomized, open-label, non-inferiority trial [version 1; peer review: awaiting peer review]
Penner, Jeremy, Ombajo, Loice, Nkuranga, Joseph, Mecha, Jared, Owuor, Kevin, Odhiambo, Collins, Mburu, Margaret, Ndinya, Florentius, Aksam, Rukia, Njenga, Richard, Wahome, Simone, Muiruri, Peter, Eshiwani, Sheila, Kimani, Maureen, Ngugi, Catherine, Pozniak, Anton
Published in F1000 research (2022)
Published in F1000 research (2022)
Get full text
Journal Article